Medtronic’s Q4 adjusted EPS of $1.55 beat estimates by $0.01 on $9.8 billion revenue, up 9.9% year-over-year and driven by a 13.8% jump in its Cardiovascular Portfolio. The company guided fiscal 2027 adjusted EPS to $5.90–$6.00 (midpoint $5.95), below the $6.06 consensus, with 6.75–7.25% organic revenue growth.
Medtronic reported adjusted EPS of $1.55 beating estimates by $0.01 on revenue of $9.8 billion, marking a 9.9% reported gain and 6.6% organic increase from the prior year period.
The company projected adjusted EPS of $5.90 to $6.00 (midpoint $5.95) for fiscal 2027, trailing the $6.06 consensus and forecasting 6.75–7.25% organic revenue growth.
The Cardiovascular Portfolio led with $3.8 billion in revenue, up 13.8% reported and 10.1% organic, while Cardiac Ablation Solutions jumped 78% globally and 124% in the U.S. Medical Surgical and Neuroscience segments grew 5.1% and 3.0% organically to $2.4 billion and $2.8 billion respectively.
For fiscal 2026, revenue reached $36.4 billion, up 8.4% reported and 5.8% organic, with adjusted EPS of $5.53. Operating cash flow was $7.3 billion, free cash flow $5.4 billion, $4.2 billion returned to shareholders and Q1 fiscal 2027 dividend raised to $0.72 per share.
Barrons
